论文部分内容阅读
通过体内实验进一步观察荷瘤小鼠放疗加骨髓移植后并用ｒｈＰＲＬ的治疗效果。选用Ｃ５７ＢＬ／６纯系小鼠，静脉注入同基因结肠腺癌细胞（ＭＣＡ－３８），待定向形成大量肺转移结节（１０ｄ）时进行全身致死放疗并进行ＳＢＭＴ，同时进行ｒｈＰＲＬ治疗。在治疗开始的１０ｄ和２０ｄ分别处死部分动物观察肺癌结节、骨髓ＣＦＵ－Ｃ、脾脏Ｔ细胞丝裂原反应与ＮＫ活性，最终计算生存期。结果表明ｒｈＰＲＬ对荷瘤小鼠具明显的治疗效果，生存期明显延长（Ｐ＜０．０１），由ＨＢＳＳ组的４３．７ｄ延至６３．１ｄ。治疗后１０ｄ和２０ｄ的肺结节数比ＨＢＳＳ组明显减少（Ｐ＜０．０１），且同时造血系统（ＣＦＵ－Ｃ）和免疫功能（Ｔ细胞和ＮＫ细胞）回升较ＨＢＳＳ组明显（均为Ｐ＜０．０１）。提示ｒｈＰＲＬ在骨髓移植模型中可促进造血系统和免疫功能的重建，从而控制肿瘤的进展并延长生存期。
Through in vivo experiments, the therapeutic effect of rhPRL was further observed in tumor-bearing mice after radiotherapy plus bone marrow transplantation. C57BL/6 pure strain mice were injected intravenously with syngeneic colon adenocarcinoma cells (MCA-38). When a large number of lung metastatic nodules (10d) were formed, systemic lethal radiotherapy and SBMT were performed simultaneously with rhPRL treatment. At 10 days and 20 days after the start of treatment, some animals were sacrificed to observe lung nodules, bone marrow CFU-C, splenic T cell mitogen response and NK activity, and finally calculate the survival period. The results showed that rhPRL had obvious therapeutic effects on tumor-bearing mice, and the survival time was significantly prolonged (P<0.01). It was delayed from 43.7 days in the HBSS group to 63.1 days. The number of pulmonary nodules at 10 d and 20 d after treatment was significantly lower than that in the HBSS group (P<0.01), and the hematopoietic system (CFU-C) and immune function (T cells and NK cells) rebounded at the same time as that in the HBSS group (both P<0.01). It is suggested that rhPRL can promote the reconstruction of hematopoietic system and immune function in the bone marrow transplantation model, so as to control the progress of the tumor and prolong the survival period.